China Drug Pricing Reform Could Be In The Works At NDRC
This article was originally published in PharmAsia News
Executive Summary
The recent clampdown on commercial bribery, highlighted by the GSK case, and a new drug cost survey from NDRC could indicate drug pricing reform in China, experts say.